The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Ocular Therapeutix completes eye drug delivery study

October 12, 2010 10:33 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Ocular Therapeutix Inc., a Bedford developer of ophthalmic therapeutic products, has closed a Proof of Principle clinical study of its moxifloxacin punctum plug, a sustained drug delivery device for post-cataract surgery.

First phase II trial of heart disease treatment for Duchenne muscular dystrophy launched

October 12, 2010 10:31 am | by EurekAlert | News | Comments

(Kennedy Krieger Institute) Kennedy Krieger announced the launch of a first-of-its-kind phase II clinical trial to investigate a treatment for heart disease in Duchenne muscular dystrophy (DMD). Made possible by a $545,000 grant from Pilot Trials Now, a DMD initiative of Charley's Fund...


Class I Medical Device Recall: Multi-Med, Inc. Huber (Non-coring) Needles and Finished Devices Containing Huber Needles Labeled as "All-Med Medical Products, Inc." and "Marque...

October 12, 2010 9:34 am | by U.S. Food & Drug Administration | News | Comments

Huber needles are safety needles used on vascular access ports implanted in patients in need of repeated intravenous therapy. A "coring" Huber needle could damage the implanted port by removing silicone slivers from the access membrane. The defect in the


Express Scripts Announces Third Quarter 2010 Earnings and 2011 Earnings Guidance Conference Call

October 12, 2010 9:32 am | by Bio-Medicine.Org | News | Comments

ST. LOUIS, Oct. 12 /- Express Scripts (Nasdaq: ESRX ), one of the largest pharmacy benefit management companies in North America, announced today its intention to release its third quarter earnings and 2011 earnings guidance on Wednesday, October 27, 2010 after the market closes and will...


Misonix Announces Change in Distribution of SonaStar® Surgical Aspiration System in the U.S.

October 12, 2010 9:32 am | by Bio-Medicine.Org | News | Comments

FARMINGDALE, N.Y., Oct. 12 /- Misonix, Inc. (Nasdaq: MSON ), a developer of state of the art, ultrasonic medical device technology, which worldwide is used for acute health conditions, has announced a definitive agreement to end its non-exclusive distribution arrangement in the United...


Results of Innovative Clinical Study Show New Combination for Weight Loss Success

October 12, 2010 9:32 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Oct. 12 /- As the weight loss and fitness industry thought leaders gathered this week to discuss the nation's obesity epidemic, a new research study presented at the conference identified a new formula for weight loss success. BodyMedia, Inc., the pioneer in developing wearable...


Burrill & Company and Infinity Group Form Joint Venture Focusing on Life Science Opportunities in China

October 12, 2010 9:32 am | by Bio-Medicine.Org | News | Comments

SAN FRANCISCO and HONG KONG, Oct. 12 /- Burrill & Company, a leading life sciences venture capital/private equity firm and Infinity Group, an RMB fund pioneer and the leading cross border China dollar and RMB private equity fund announced today that they have established a strategic...


General Dynamics Awarded Contract to Outfit and Transition U.S. Army Medical Facilities

October 12, 2010 9:31 am | by Bio-Medicine.Org | News | Comments

FAIRFAX, Va., Oct. 12 /- General Dynamics Information Technology, a business unit of General Dynamics (NYSE: GD ), has been awarded a contract to support the U.S. Army Medical Department's healthcare construction projects, including modernization of current Army medical facilities and...


Professional Liability Costs for Hospitals and Physicians Continue to Rise, Outpacing Inflation

October 12, 2010 9:31 am | by Bio-Medicine.Org | News | Comments

CHICAGO, Oct. 12 /- Hospitals and physicians should prepare for increasing liability costs , according to the 2010 Hospital Professional Liability and Physician Liability Benchmark Analysis created by Aon Risk Solutions , the global risk management business of Aon Corporation (NYSE: AON...


Public Workshop - Innovations in Technology for the Treatment of Diabetes: Clinical Development of the Artificial Pancreas (an Autonomous System), November 10, 2010

October 12, 2010 7:34 am | by U.S. Food & Drug Administration | News | Comments

An Artificial Pancreas is a medical device that links a glucose monitor to an insulin infusion pump where the pump automatically takes action (using a control algorithm) based upon the glucose monitor reading...

Heart device firm InfraReDX lands $21M financing

October 12, 2010 7:34 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Burlington-based medical device firm InfraReDx Inc. has completed a $21 million equity funding, intended for the commercial launch of its LipiScan IVUS Coronary Imaging System.

WPI Holdings Acquires Wilmington Medical Supply Inc.

October 12, 2010 7:34 am | by Bio-Medicine.Org | News | Comments

OCEANSIDE, N.Y., Oct. 12 /- WPI Holdings d/b/a Woodbury Health Products ("Woodbury"), a portfolio company of HealthEdge Investment Partners, LLC ("HealthEdge"), announced today that it has completed the acquisition of Wilmington Medical Supply Inc. ("WMS"). Based in Wilmington, North...


Siemens Awarded New Premier Contracts for Hemostasis, Urinalysis and Microbiology Product Lines

October 12, 2010 7:32 am | by Bio-Medicine.Org | News | Comments

DEERFIELD, Ill., Oct. 12 /- Siemens Healthcare Diagnostics announces new three-year agreements with Premier Purchasing Partners, LP, the group purchasing unit of Premier Inc., for hemostasis, urinalysis and microbiology systems and reagents, and sole source contracts for Premier's ASCEND...


Halozyme cutting 25 percent of its work force

October 12, 2010 6:45 am | by The Associated Press | News | Comments

Halozyme Therapeutics Inc. said Tuesday it will cut 25 percent of its work force in a restructuring move.The company said it will decrease research relating to the discovery and preclinical assessment of new compounds, and instead focus on its core programs. Those programs include its midstage...

Incept BioSystems Completes First Human Clinical Trial of the SMART Start™ Embryo Culture System and Submits 510(k) Application to the FDA

October 12, 2010 6:31 am | by Bio-Medicine.Org | News | Comments

ANN ARBOR, Mich., Oct. 12 /- Incept BioSystems, Inc. ("Incept"), a privately-held biomedical device company using patented, microfluidic technology developed at the University of Michigan, announced today the completion of the first U.S. human clinical trial of its proprietary, SMART...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.